Haemonetics (NYSE:HAE) Given New $86.00 Price Target at JPMorgan Chase & Co.

Key Points

• JPMorgan raised Haemonetics’ price target from $62 to $86 while maintaining a “neutral” rating, implying only 0.17% upside from the stock’s $85.85 trading price.
• Analyst sentiment remains broadly positive: Haemonetics has a consensus “Moderate Buy” rating and an average price target of $88.44, with targets ranging up to $105.
• The company exceeded quarterly expectations, reporting $1.14 in EPS and $339.38 million in revenue, while revenue increased 5.5% year over year; institutional investors own 99.67% of the stock.

Haemonetics (NYSE:HAE - Get Free Report) had its price objective increased by equities researchers at JPMorgan Chase & Co. from $62.00 to $86.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a "neutral" rating on the medical instruments supplier's stock. JPMorgan Chase & Co.'s price target would indicate a potential upside of 0.17% from the company's current price.

A number of other analysts have also recently issued reports on HAE. Citigroup restated a "buy" rating on shares of Haemonetics in a research report on Wednesday, July 29th. Robert W. Baird set a $96.00 target price on shares of Haemonetics in a research report on Friday. Weiss Ratings upgraded shares of Haemonetics from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, June 25th. Raymond James Financial reissued an "outperform" rating and issued a $105.00 price target on shares of Haemonetics in a research note on Friday. Finally, Bank of America raised Haemonetics from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $72.00 to $80.00 in a research note on Friday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Haemonetics presently has a consensus rating of "Moderate Buy" and a consensus price target of $88.44.

Haemonetics Stock Performance

Shares of HAE stock traded up $0.83 during trading hours on Friday, reaching $85.85. The stock had a trading volume of 136,513 shares, compared to its average volume of 850,258. The firm has a market capitalization of $3.90 billion, a PE ratio of 42.44, a price-to-earnings-growth ratio of 1.69 and a beta of 0.52. The firm has a 50-day simple moving average of $76.59 and a 200-day simple moving average of $66.37. Haemonetics has a twelve month low of $47.31 and a twelve month high of $88.58. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.06. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The company had revenue of $339.38 million during the quarter, compared to analyst estimates of $327.86 million. During the same quarter in the previous year, the firm posted $1.10 EPS. The firm's quarterly revenue was up 5.5% on a year-over-year basis. As a group, equities analysts forecast that Haemonetics will post 5.21 earnings per share for the current year.

Hedge Funds Weigh In On Haemonetics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC lifted its stake in shares of Haemonetics by 372.8% in the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier's stock valued at $102,814,000 after acquiring an additional 1,678,630 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Haemonetics by 994.7% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier's stock valued at $110,615,000 after purchasing an additional 1,254,035 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Haemonetics by 4,296.3% during the third quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier's stock valued at $37,685,000 after purchasing an additional 755,592 shares in the last quarter. North Peak Capital Management LLC grew its holdings in shares of Haemonetics by 204.4% during the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier's stock worth $88,405,000 after purchasing an additional 740,626 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Haemonetics in the third quarter valued at approximately $15,703,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Quarterly results exceeded expectations. Haemonetics reported fiscal Q1 2027 earnings of $1.14 per share, above the $1.07–$1.08 analyst consensus and up from $1.10 a year earlier. Revenue reached $339.38 million, surpassing the $327.86 million consensus and increasing 5.5% year over year. Haemonetics Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2027 outlook. The company now forecasts reported revenue growth of approximately 5% to 8% for fiscal 2027, with full-year revenue guidance of roughly $1.4 billion. The improved outlook reflects the strong first-quarter performance and provides support for the stock’s earnings-growth narrative. Haemonetics Raises Fiscal 2027 Revenue Guidance
• Positive Sentiment: BTIG Research raised its price target. BTIG increased its target for Haemonetics from $84 to $96 and reiterated a “Buy” rating, signaling additional potential upside based on the company’s results and outlook. BTIG Raises Haemonetics Price Target
• Negative Sentiment: Initial market reaction was cautious. Despite the earnings beat, reports indicated that the stock declined in premarket trading, suggesting investors may have expected an even stronger outlook or may be taking profits after the recent advance. Haemonetics also trades at a relatively high forward valuation, which can increase sensitivity to guidance and execution.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source